MeiraGTx Holdings plc (MGTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol MGTX
- Company MeiraGTx Holdings plc
- Price $8.25
- Changes Percentage 28.71
- Change 1.84
- Day Low $7.4
- Day High $8.49
- Year High $8.49
- Year Low $3.85
- Market Cap $644,765,550
- Price Avg 50 EMA (D) $6.49
- Price Avg 200 EMA (D) $5.38
- Exchange NASDAQ
- Volume 6,273,833
- Average Volume 419,684
- Open $7.73
- Previous Close $6.41
- EPS -2.12
- PE -3.89
- Earnings Announcement 2025-05-07 12:30:00
- Shares Outstanding $78,153,400
Company brief: MEIRAGTX HOLDINGS PLC (MGTX )
- Healthcare
- Biotechnology
- Dr. Alexandria Forbes Ph.D.
- https://www.meiragtx.com
- US
- N/A
- 06-08-2018
- KYG596651029
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Corporation News
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
globenewswire.com -- - Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 millio...
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process
globenewswire.com -- - MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen ...